What is Amazon Bio Discovery, and how does it accelerate early-stage drug discovery?

Amazon Bio Discovery is an AI application launched by Amazon Web Services (AWS) to speed early-stage drug discovery by enabling scientists to run complex computational workflows without writing code. It provides access to specialized biological foundation models that can generate and evaluate potential drug molecules, along with an AI agent that helps users select models, set parameters, and interpret results. Researchers can send shortlisted candidates to integrated lab partners for synthesis and testing, with results fed back into the system to guide subsequent design cycles — reducing the time to generate 300 potential drug candidates from 18 months to a couple of weeks.

Who are the early adopters and key collaborators of Amazon Bio Discovery, and what real-world impact has it demonstrated?

Early adopters include Bayer, the Broad Institute, and Voyager Therapeutics; 19 of the top 20 global pharmaceutical companies already use AWS cloud services. In collaboration with Memorial Sloan Kettering Cancer Center, the platform used multiple models to generate nearly 300,000 novel antibody molecules and narrow them to 100,000 candidates for lab testing by Twist Bioscience — compressing work that typically takes months into weeks.

Amazon launches AI research tool to speed early-stage drug discovery

Apr 14, 2026

AWS launched Amazon Bio Discovery, an AI tool accelerating drug discovery by generating thousands of molecular candidates rapidly. Major pharma firms including Bayer and Merck are adopting the platform to streamline research workflows and reduce development timelines.

reuters

2026-04-14

Amazon launches AI research tool to speed early-stage drug discovery

Amazon launches AI research tool to speed early-stage drug discovery

FAQ